Catalyst Event
Eli Lilly and Co (LLY) · Other
From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)
3/19/2026, 12:00:00 AM
Announced positive topline results from the Phase 3 trial of retatrutide for type 2 diabetes, showing significant reductions in both blood sugar and weight.
Korean Translation
제2형 당뇨병 치료제 레타트루타이드(retatrutide)의 3상 임상시험에서 혈당과 체중 모두에서 유의미한 감소를 보인 긍정적인 탑라인 결과를 발표함.
Related Recent Events
CrowdStrike Holdings Inc (CRWD) · Earnings Release
Next earnings release for Q1 2027 is scheduled for 2026-06-09, with analysts forecasting an EPS of $1.07 estimated.
6/9/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
U.S. FDA decision (PDUFA date) for LEQEMBI IQLIK (lecanemab) subcutaneous autoinjector for treatment initiation in Alzheimer's disease on 2026-05-24; high importance is estimated as FDA approval for a major drug formulation typically results in ≥10% price impact, scheduled.
5/24/2026, 12:00:00 AM
Walmart Inc (WMT) · Earnings Release
Walmart's earnings release for Q1 FY2027 is scheduled. A medium impact is estimated as earnings releases are key volatility drivers for retail stocks, expected.
5/21/2026, 12:00:00 AM
ONEOK Inc (OKE) · Other
ONEOK 2026 Annual Meeting of Shareholders on May 20, 2026, scheduled.
5/20/2026, 12:00:00 AM
Fair Isaac Corporation (FICO) · Other
FICO World 2026 is scheduled to take place from May 19-22, 2026.
5/19/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Other
Google I/O 2026 developer conference is scheduled for 2026-05-19. Developer conferences usually have a 1-5% price impact. Updates on AI, Gemini, and Android are expected.
5/19/2026, 12:00:00 AM